Tomoya Fukui

ERRATUM: Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study

Naoya Nishioka, Tae Hata, Tadaaki Yamada, Yasuhiro Gotô et autres

jp (code pays fourni par la source)

Heat‐Induced Granular Motion in Quasi‐Solid‐State Suzuki–Miyaura Reaction

Boško Vrbica, Z E Zhang, Abhijit Sen, Aya Ohno et autres

Solid-state cross-coupling is a promising synthetic strategy, enabling green processes and access to otherwise unattainable products. To date, avoiding the harsh mechanical force while achieving the synthesis of highly insoluble materials under mild, additive-free, and solid-state conditions remains a challenge especially if …

jp, us (code pays fourni par la source)

Heat-Induced Granular Motion in Quasi-Solid-State Suzuki–Miyaura Reaction

Tomoya Fukui, Takanori Fukushima

Solid-state cross-coupling is a promising synthetic strategy, enabling green processes and access to otherwise unattainable products. To date, avoiding the harsh mechanical force while achieving the synthesis of highly insoluble materials under mild, additive-free, and solid-state conditions remains a challenge especially if …

Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression

Aosa Sasada, Hayato Kawachi, Tadaaki Yamada, Yasuhiro Gotô et autres

Background/Aim: Establishing the suitability of initiating immune checkpoint inhibitor (ICI) therapy in patients with lung cancer and coexisting interstitial pneumonia (IP) is challenging. Real-world evidence on the efficacy and safety of ICIs in such patients is urgently needed to inform clinical practice. …

jp (code pays fourni par la source)

Author response for "Wrapping a single crystal spin-crossover complex with a single crystal non-spin-crossover complex to modulate the spin-transition temperature"

Tomoya Fukui, Masahiro Tsuchiya, Naoya Mita, Takanori Fukushima

Self-Stirring Drives Solid-State Suzuki–Miyaura Reaction with Real-Time Visualization

Boško Vrbica, Zhenzhong Zhang, Abhijit Sen, Aya Ohno et autres

Solid-state cross-coupling is a promising synthetic strategy, enabling green processes and access to otherwise unattainable products. Inspired by the fundamental diffusion dynamics observed in nature, we developed a polymeric palladium-catalyzed solid-state Suzuki–Miyaura reaction that proceeds without mechanical input, that is, self-stirring of …

jp (code pays fourni par la source)

1930P A ctDNA-derived tumor DNA methylation score as a predictive biomarker of treatment response in advanced non-small cell lung cancer: LC-SCRUM-MRD

Shingo Kitagawa, Y. Zenke, K. Yoh, Tomoya Fukui et autres

jp (code pays fourni par la source)

Real-world evidence on the survival benefit of immune checkpoint inhibitors in combination with cytotoxic chemotherapy for patients with extensive-disease small-cell lung cancer: the Tokushukai Real World Data Project (TREAD) 06

Tomoya Fukui, Yoshinori Imamura, Takuya Kakutani, Kiyoaki Uryu et autres

BACKGROUND: Small-cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis. Despite the initial chemosensitivity, survival for extensive-disease (ED) SCLC remains limited. Immune checkpoint inhibitors (ICIs) in combination with chemotherapy have recently been redefined as the standard of care. We …

jp (code pays fourni par la source)

Figure 3 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

Tae Hata, Tadaaki Yamada, Yasuhiro Gotô, Akihiko Amano et autres

Treatment outcomes according to liver metastases. The Kaplan–Meier curves provide estimates of OS (A) and PFS (B) of the patients with liver metastases stratified by treatment with ICI plus chemotherapy and chemotherapy (n = 76). OS (C) and PFS (D) of the …

Data from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

Tae Hata, Tadaaki Yamada, Yasuhiro Gotô, Akihiko Amano et autres

Abstract Chemoimmunotherapy is recommended for patients with non–small cell lung cancer (NSCLC) with low PD-L1 expression, but the effect of additional immunotherapy is heterogeneous in this population. To identify patients who do not benefit from the addition of immune checkpoint inhibitors (ICI) …

Supplementary Table S1 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

Tae Hata, Tadaaki Yamada, Yasuhiro Gotô, Akihiko Amano et autres

Patients Characteristics

Supplementary Figure S2 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

Tae Hata, Tadaaki Yamada, Yasuhiro Gotô, Akihiko Amano et autres

Overall survival and Progression-free survival of 851 patients according to treatments